Histone variant H2A.Z.2: A novel driver of melanoma progression

Chiara Vardabasso; Sandra B. Hake; Emily Bernstein

doi:10.1080/23723556.2015.1073417

Histone variant H2A.Z.2: A novel driver of melanoma progression

Chiara Vardabasso
, Sandra B. Hake
, Emily Bernstein

Research output: Contribution to journal › Article › peer-review

18 Scopus citations

Abstract

Histone variants are attracting attention in the field of cancer epigenetics. Our study has established a novel role for the uncharacterized histone variant H2A.Z.2 as a driver of malignant melanoma. H2A.Z.2 promotes cellular proliferation by recruiting BRD2 and E2F1 to E2F target genes and facilitating their transcription. High H2A.Z.2 expression correlates with poor survival in patients, and its depletion sensitizes cells to chemotherapy and targeted therapies.

Original language	English
Article number	e1073417
Journal	Molecular and Cellular Oncology
Volume	3
Issue number	2
DOIs	https://doi.org/10.1080/23723556.2015.1073417
State	Published - 3 Mar 2016

Keywords

BET
BRD2
E2F
H2A.Z
chromatin
histone variants
melanoma

Access to Document

10.1080/23723556.2015.1073417

Cite this

@article{3a45ae04a2fb4c29b51351e712f3fc6e,

title = "Histone variant H2A.Z.2: A novel driver of melanoma progression",

abstract = "Histone variants are attracting attention in the field of cancer epigenetics. Our study has established a novel role for the uncharacterized histone variant H2A.Z.2 as a driver of malignant melanoma. H2A.Z.2 promotes cellular proliferation by recruiting BRD2 and E2F1 to E2F target genes and facilitating their transcription. High H2A.Z.2 expression correlates with poor survival in patients, and its depletion sensitizes cells to chemotherapy and targeted therapies.",

keywords = "BET, BRD2, E2F, H2A.Z, chromatin, histone variants, melanoma",

author = "Chiara Vardabasso and Hake, \{Sandra B.\} and Emily Bernstein",

note = "Publisher Copyright: {\textcopyright} 2016, {\textcopyright} 2016 Taylor \& Francis Group, LLC.",

year = "2016",

month = mar,

day = "3",

doi = "10.1080/23723556.2015.1073417",

language = "English",

volume = "3",

journal = "Molecular and Cellular Oncology",

issn = "2372-3556",

publisher = "Taylor and Francis Ltd.",

number = "2",

}

TY - JOUR

T1 - Histone variant H2A.Z.2

T2 - A novel driver of melanoma progression

AU - Vardabasso, Chiara

AU - Hake, Sandra B.

AU - Bernstein, Emily

PY - 2016/3/3

Y1 - 2016/3/3

N2 - Histone variants are attracting attention in the field of cancer epigenetics. Our study has established a novel role for the uncharacterized histone variant H2A.Z.2 as a driver of malignant melanoma. H2A.Z.2 promotes cellular proliferation by recruiting BRD2 and E2F1 to E2F target genes and facilitating their transcription. High H2A.Z.2 expression correlates with poor survival in patients, and its depletion sensitizes cells to chemotherapy and targeted therapies.

AB - Histone variants are attracting attention in the field of cancer epigenetics. Our study has established a novel role for the uncharacterized histone variant H2A.Z.2 as a driver of malignant melanoma. H2A.Z.2 promotes cellular proliferation by recruiting BRD2 and E2F1 to E2F target genes and facilitating their transcription. High H2A.Z.2 expression correlates with poor survival in patients, and its depletion sensitizes cells to chemotherapy and targeted therapies.

KW - BET

KW - BRD2

KW - E2F

KW - H2A.Z

KW - chromatin

KW - histone variants

KW - melanoma

UR - https://www.scopus.com/pages/publications/85043564400

U2 - 10.1080/23723556.2015.1073417

DO - 10.1080/23723556.2015.1073417

M3 - Article

AN - SCOPUS:85043564400

SN - 2372-3556

VL - 3

JO - Molecular and Cellular Oncology

JF - Molecular and Cellular Oncology

IS - 2

M1 - e1073417

ER -

Histone variant H2A.Z.2: A novel driver of melanoma progression

Abstract

Keywords

Access to Document

Fingerprint

Cite this